Related Experiment Videos
Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis
Henry J Kaminski1, Zhuyi Li, Chelliah Richmonds
1Department of Neurology, Louis Stokes Cleveland Veterans Affairs Medical Center, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA. Henry.Kaminski@case.edu
Experimental Neurology
|September 24, 2004
Summary
Extraocular muscles (EOM) show lower complement regulator mRNA and protein, increasing susceptibility to myasthenia gravis (MG). Complement inhibitors may treat ocular MG.
Area of Science:
- Neuroimmunology
- Complement system biology
- Skeletal muscle physiology
Background:
- Complement activation at motor endplates is the primary mechanism in myasthenia gravis (MG).
- Extraocular muscles (EOM) are more susceptible to MG than other skeletal muscles.
- Cell-surface complement regulators play a role in MG pathogenesis.
Purpose of the Study:
- To investigate if differences in gene transcript and protein expression of complement regulators contribute to EOM susceptibility in MG.
- To compare complement regulator expression in EOM versus diaphragm under normal and experimental autoimmune MG (EAMG) conditions.
Main Methods:
- Experimental autoimmune MG (EAMG) induced in mice using anti-acetylcholine receptor (AChR) monoclonal antibody.
- Quantitative PCR (qPCR) to measure mRNA levels of complement regulators (DAF, CD59, Crry) and AChR subunits.
- Immunohistochemistry to assess protein expression of complement regulators at neuromuscular junctions.
Main Results:
- EOM exhibited lower constitutive mRNA levels of DAF, CD59, and Crry, but higher AChR subunit mRNA compared to diaphragm.
- EAMG induced significant decreases in complement regulator and AChR subunit mRNA in EOM, but not diaphragm.
- Immunohistochemistry revealed lower complement regulator expression at EOM junctions compared to diaphragm junctions.
Conclusions:
- Diminished intrinsic complement regulatory activity in EOM may underlie their increased susceptibility to MG.
- Findings suggest complement inhibitor-based therapies could be beneficial for ocular MG.
- Understanding complement regulation differences is crucial for targeted MG therapies.